Focused on developing novel treatments for retinal diseases
IVERIC is focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company’s lead asset is Zimura (avacincaptad pegol), an aptamer targeting complement factor C5, which is a central component of the complement cascade believed to be involved in the development of age-related macular degeneration (AMD), geographic atrophy (GA), and other retinal diseases.
